Page last updated: 2024-11-05

ticlopidine and Cerebral Ischemia

ticlopidine has been researched along with Cerebral Ischemia in 264 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."9.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel."9.27Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. ( Cheng, W; Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA."9.24Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017)
"In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia."9.22Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016)
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."9.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial."9.16Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012)
"The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke."9.14Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009)
"The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)."9.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."9.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."9.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."9.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study."9.11Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005)
"In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks."9.10Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003)
" In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke."9.10Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."9.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions."8.89Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."8.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)."8.84Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008)
"It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting."7.96Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."7.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
"To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients."7.88Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."7.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"To assess the association of CYP2C19 gene polymorphisms with the incidence of ischemic stroke among patients receiving clopidogrel therapy following coronary stenting for coronary artery disease."7.85[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. ( Chen, J; Ding, N; Li, G; Peng, L; Shao, Y; Wang, Y; Xu, Z; Zhang, C, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."7.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."7.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
" We examined the influence of low response to clopidogrel on symptomatic ischemic events and new ischemic MRI lesions with endovascular intracranial aneurysmal coil embolization."7.83Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. ( Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Ota, K; Shintai, K; Tajima, H; Wakabayashi, T; Yamanouchi, T, 2016)
"We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)."7.83Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016)
" Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment."7.83Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016)
"We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years."7.83Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016)
"Despite clopidogrel has been widely applied to patients with ischemic stroke combined with aspirin, decreased metabolic activation of clopidogrel still occurs because of genetic variations in CYP2C19."7.83Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel. ( Cai, H; Liu, X; Wang, Y; Zhang, Z; Zhou, G, 2016)
" We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel."7.81CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015)
"PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel."7.81Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. ( Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE, 2015)
" The aim of this study was to validate the predictive value of HRPR measured by flow cytometry for clinical outcomes in ischemic stroke patients during clopidogrel therapy."7.81Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. ( Han, RF; Li, X; Liu, J; Qiu, LN; Wang, L; Xia, XS, 2015)
"This study sought to evaluate the influence of the genetic polymorphisms on platelet reactivity and clinical outcomes in acute ischemic stroke patients taking clopidogrel."7.81Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. ( Dong, Q; Guan, YT; Han, Y; Jiang, JM; Li, SX; Liu, X; Luo, Z; Lv, HH; Wu, S; Xu, JF; Yang, XL; Zhang, Y; Zheng, Y; Zhu, DS, 2015)
"A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated."7.80Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014)
"We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months."7.80Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)
"Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients."7.80VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014)
"The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence trial raised concern that loading doses of clopidogrel may increase hemorrhagic complications."7.79Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients. ( Albright, KC; Beasley, TM; Boehme, AK; Jones, EM; Leung, LY; Martin-Schild, S; Pletsch, GR; Shah, KR; Siegler, JE; Tarsia, J, 2013)
"Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common."7.79Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013)
"This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)."7.79Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013)
" In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques."7.78Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012)
"A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update."7.76Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."7.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
" We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)."7.75Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009)
"Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke."7.74ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008)
"The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)."7.73The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006)
"Acute cerebral ischemia was produced in rats by injection of arachidonic acid (AA) into the internal carotid artery."7.68Protective effects of benidipine on arachidonic acid-induced acute cerebral ischemia in rats. ( Karasawa, A; Kubo, K; Sano, J; Shirakura, S, 1992)
"Stress hyperglycemia was measured by glucose/glycated albumin (GA) ratio."6.84Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Cai, X; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wei, T; Zhao, X, 2017)
"The primary outcome is IS recurrence."6.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
" Dosage was maintained as 75mg clopidogrel daily, 250mg ticlopidine twice daily, and 250mg ticlopidine plus 80mg Gingko Biloba extract twice daily."6.78Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia. ( Hong, JM; Joo, IS; Lee, JS; Lim, YA; Shin, DH, 2013)
"HPR-aspirin was persistent 75days later in 36% patients."5.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."5.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel."5.27Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. ( Cheng, W; Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA."5.24Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017)
"In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia."5.22Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016)
" In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone."5.22The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016)
"Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke."5.20Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015)
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."5.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score."5.17The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013)
"We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension."5.16Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012)
"We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel."5.16Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012)
"We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.16Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012)
"The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke."5.14Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009)
"The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)."5.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."5.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."5.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
"Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion."5.13Platelet aggregation and recruitment with aspirin-clopidogrel therapy. ( Brace, LD; Cursio, J; Grossi, E; Helgason, CM; Pandey, D; Valika, A, 2008)
"We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel."5.11Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."5.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study."5.11Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005)
"In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks."5.10Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003)
" In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke."5.10Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."5.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved."4.90Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014)
"The impact of PPI use on the 1-year primary end point (ischemic stroke, myocardial infarction [MI], or vascular death) in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial and the 28-day (all-cause death, MI, or urgent target vessel revascularization) and 1-year (all-cause death, MI, or stroke) primary end points in the Clopidogrel for Reduction of Events During Observation (CREDO) trial were examined."4.89Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. ( Bauer, D; Berger, PB; Charnigo, RJ; Dunn, SP; Steinhubl, SR; Topol, EJ, 2013)
"Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0."4.89Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013)
"This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions."4.89Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013)
" In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3."4.88Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."4.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."4.87Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
"In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women."4.85Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009)
" Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive."4.85Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009)
"The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)."4.84Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008)
"It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting."3.96Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."3.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
" After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1."3.88STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke. ( Bonetti, B; Bovi, P; Cappellari, M; Forlivesi, S; Toni, D; Turcato, G; Zivelonghi, C, 2018)
"To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients."3.88Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"We studied 671 myocardial infarction (MI) patients treated with percutaneous coronary intervention in the TRANSLATE-ACS Registry who had VerifyNow platelet function testing performed while on clopidogrel treatment during their index hospitalization (April 2010-October 2012)."3.85Association of measured platelet reactivity with changes in P2Y ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME, 2017)
" A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness."3.85Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. ( Bigliardi, G; Dell'Acqua, ML; Ferraro, D; Lelli, N; Mimmi, S; Nichelli, P; Pentore, R; Picchetto, L; Rosafio, F; Trenti, T; Vandelli, L; Zini, A, 2017)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."3.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"To assess the association of CYP2C19 gene polymorphisms with the incidence of ischemic stroke among patients receiving clopidogrel therapy following coronary stenting for coronary artery disease."3.85[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. ( Chen, J; Ding, N; Li, G; Peng, L; Shao, Y; Wang, Y; Xu, Z; Zhang, C, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."3.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."3.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
" We examined the influence of low response to clopidogrel on symptomatic ischemic events and new ischemic MRI lesions with endovascular intracranial aneurysmal coil embolization."3.83Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. ( Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Ota, K; Shintai, K; Tajima, H; Wakabayashi, T; Yamanouchi, T, 2016)
"We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)."3.83Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016)
" Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment."3.83Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016)
"We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years."3.83Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016)
"From a cohort of 1900 patients with ischemic stroke, we selected 42 patients treated with clopidogrel, including 21 with a recurrent vascular event and 21 without vascular recurrence during the first year of follow-up."3.83TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. ( Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016)
"Despite clopidogrel has been widely applied to patients with ischemic stroke combined with aspirin, decreased metabolic activation of clopidogrel still occurs because of genetic variations in CYP2C19."3.83Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel. ( Cai, H; Liu, X; Wang, Y; Zhang, Z; Zhou, G, 2016)
" We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel."3.81CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015)
"PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel."3.81Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. ( Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE, 2015)
" The aim of this study was to validate the predictive value of HRPR measured by flow cytometry for clinical outcomes in ischemic stroke patients during clopidogrel therapy."3.81Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. ( Han, RF; Li, X; Liu, J; Qiu, LN; Wang, L; Xia, XS, 2015)
"This study sought to evaluate the influence of the genetic polymorphisms on platelet reactivity and clinical outcomes in acute ischemic stroke patients taking clopidogrel."3.81Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. ( Dong, Q; Guan, YT; Han, Y; Jiang, JM; Li, SX; Liu, X; Luo, Z; Lv, HH; Wu, S; Xu, JF; Yang, XL; Zhang, Y; Zheng, Y; Zhu, DS, 2015)
"In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke."3.81Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015)
"To assess the association of genetic polymorphisms of CYP2C19*2,*3,*17 with the recurrence risk of ischemic stroke during clopidogrel prevention in ethnic Han Chinese from Fujian Province."3.81[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian]. ( Fang, L; Huang, H; Lin, M; Wang, N; Yang, Z; Zhao, Y, 2015)
"A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated."3.80Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014)
"We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months."3.80Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)
"We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke."3.80Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014)
"Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients."3.80VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014)
"The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence trial raised concern that loading doses of clopidogrel may increase hemorrhagic complications."3.79Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients. ( Albright, KC; Beasley, TM; Boehme, AK; Jones, EM; Leung, LY; Martin-Schild, S; Pletsch, GR; Shah, KR; Siegler, JE; Tarsia, J, 2013)
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation."3.79The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013)
" P2Y12 (+/-) or clopidogrel treated mice subjected to global cerebral ischemia suffered less neuronal injury (P<0."3.79Microglial P2Y12 deficiency/inhibition protects against brain ischemia. ( Hokari, M; Kacimi, R; Ma, H; McManus, A; Tang, XN; Webster, CM; Yenari, MA, 2013)
"Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common."3.79Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013)
"This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)."3.79Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013)
" The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis."3.79Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013)
"In patients with ischemic stroke or transient ischemic attack, 43% (n=128) and 35% (n=54) were nonresponders to aspirin and clopidogrel, respectively."3.78Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. ( Bakdash, S; Bhatt, DL; Depta, JP; Fowler, J; Katzan, I; Kottke-Marchant, K; Novak, E, 2012)
" In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques."3.78Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization."3.76Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010)
"A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update."3.76Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."3.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
" We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)."3.75Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009)
"We sought to correlate the inhibition of platelet aggregation (IPA) with plasma levels of unchanged clopidogrel (UC), active thiol metabolite (ATM), and inactive carboxyl metabolite (ICM) in a large cohort of patients with coronary artery disease and ischemic stroke treated with clopidogrel."3.75Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". ( Atar, D; Booze, C; Cherala, G; Kuliczkowski, W; Serebruany, V; Surigin, S; Williams, C, 2009)
"Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke."3.74ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008)
"Patients with ischemic stroke enrolled in the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study underwent long-term prospective assessment of their modified Rankin Scale (mRS) score."3.74Rate, degree, and predictors of recovery from disability following ischemic stroke. ( Bego, G; Carita, P; Gabriel, S; Hakimi, Z; Hankey, GJ; Spiesser, J, 2007)
"In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)."3.74[Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007)
"We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)."3.73Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005)
" The antiplatelet drugs acetylsalicylic acid (aspirin) and a thienopyridine derivative (ticlopidine) are commonly used to treat cerebral ischemia but exert different effects on high-shear-stress-induced platelet aggregation (H-SIPA) in the plasma."3.73Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. ( Fujimura, Y; Iida, J; Ishizashi, H; Kawaguchi, S; Matsumoto, M; Sakaki, T; Yagi, H, 2005)
"The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)."3.73The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006)
" Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy."3.73Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006)
"Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial."3.72Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004)
"The results with GP in acute ischemic stroke are promising and further studies should be initiated using especially tirofiban, but with monitoring by cerebral diffusion-weighted MRI before and after treatment."3.72[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice]. ( Haerten, K; Krabbe, C; Raiber, M, 2004)
"Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease."3.70Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999)
"Acute cerebral ischemia was produced in rats by injection of arachidonic acid (AA) into the internal carotid artery."3.68Protective effects of benidipine on arachidonic acid-induced acute cerebral ischemia in rats. ( Karasawa, A; Kubo, K; Sano, J; Shirakura, S, 1992)
"Stress hyperglycemia was measured by glucose/glycated albumin (GA) ratio."2.84Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Cai, X; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wei, T; Zhao, X, 2017)
"The primary outcome is IS recurrence."2.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
" The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI."2.79Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" Dosage was maintained as 75mg clopidogrel daily, 250mg ticlopidine twice daily, and 250mg ticlopidine plus 80mg Gingko Biloba extract twice daily."2.78Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia. ( Hong, JM; Joo, IS; Lee, JS; Lim, YA; Shin, DH, 2013)
"The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI."2.76Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011)
"Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events."2.68A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996)
"Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction."2.68[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996)
"The subjects were 75 patients with cerebral ischemia and 26 control subjects."2.67Shear-induced platelet aggregation in cerebral ischemia. ( Fukuyama, M; Handa, M; Ikeda, Y; Itagaki, I; Maruyama, S; Uchiyama, S; Yamazaki, M, 1994)
"048), and the frequency of adverse events was not significantly different between the two treatment groups."2.67The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993)
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."2.52Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)
"Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot."2.45Antiplatelet treatment in ischemic stroke treatment. ( Arnao, V; Di Raimondo, D; Di Sciacca, R; La Placa, S; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2009)
"Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States."2.44Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008)
"Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]."2.44Antithrombotic treatment in the prevention of ischemic stroke. ( Emre, U; Rantanen, K; Tatlisumak, T, 2007)
"Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies."2.43Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"Ticlopidine is a reserve drug due to its unfavorable side effect profile (neutropenia, TTP)."2.42[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review]. ( Jüttler, E; Meyding-Lamadé, UK; Schellinger, PD; Schwark, C, 2004)
"Ticlopidine is a thienopyridine derivative which reduces the risk of reversible ischaemia and stroke in patients who have previously experienced a cerebral ischaemic episode."2.39Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. ( Goa, KL; Noble, S, 1996)
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."1.51The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)
"The aspirin reaction unit was blindly measured at the following two times: after 3 hours of aspirin loading and on the fifth day of aspirin administration."1.48Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Kim, JT; Lee, JS; Park, MS; Saver, JL, 2018)
"HPR-aspirin was persistent 75days later in 36% patients."1.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."1.37Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size."1.36Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010)
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."1.36Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)
" In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)."1.35Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008)
"Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury."1.34TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007)
"Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion."1.33Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005)
"Poststroke recurrence rate was low (7."1.32Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003)
"Vascular dementia is a common and potentially reversible type of dementing illness."1.27Validation of cognitive and functional assessment instruments in vascular dementia. ( Greenough, PG; Hershey, LA; Jaffe, DF; Yang, SL, 1987)

Research

Studies (264)

TimeframeStudies, this research(%)All Research%
pre-19907 (2.65)18.7374
1990's35 (13.26)18.2507
2000's75 (28.41)29.6817
2010's141 (53.41)24.3611
2020's6 (2.27)2.80

Authors

AuthorsStudies
Guo, Y1
Zhao, J1
Zhang, Y3
Wu, L1
Yu, Z1
He, D1
Huang, H2
Qu, W1
Luo, X1
Xu, J1
Xu, X1
Wang, H1
He, L1
Liu, Q1
Du, Y1
Wang, J1
Pan, YS1
Wang, YJ2
Kumar, A1
Shariff, M1
Doshi, R1
Song, TJ1
Kim, J1
Han, SW2
Kim, YD1
Lee, JY1
Ahn, SH2
Lee, HS1
Jung, YH1
Lee, KY2
Yuan, HW1
Lin, YJ1
Ji, RJ1
Wong, YS1
Tsai, CF1
Hsu, YH1
Ong, CT1
Pan, Y4
Jing, J4
Chen, W1
Meng, X3
Li, H4
Zhao, X4
Liu, L4
Wang, D3
Johnston, SC7
Wang, Y12
Fiolaki, A1
Katsanos, AH1
Kyritsis, AP1
Papadaki, S1
Kosmidou, M1
Moschonas, IC1
Tselepis, AD1
Giannopoulos, S1
Bagai, A1
Peterson, ED1
McCoy, LA1
Effron, MB1
Zettler, ME1
Stone, GW2
Henry, TD1
Cohen, DJ1
Schulte, PJ1
Anstrom, KJ1
Wang, TY1
Rosafio, F1
Lelli, N1
Mimmi, S1
Vandelli, L1
Bigliardi, G1
Dell'Acqua, ML1
Picchetto, L1
Pentore, R1
Ferraro, D1
Trenti, T1
Nichelli, P1
Zini, A1
Rao, Z1
Zheng, H1
Wang, F1
Wang, A1
Dong, K2
Cao, Y1
Milionis, H2
Ntaios, G1
Papavasileiou, V1
Spengos, K1
Manios, E1
Elisaf, M1
Vemmos, K1
Ikeda-Sakai, Y1
Sasaki, M1
Nakase, T1
Han, YF1
Dai, QL1
Chen, XL1
Xiong, YY1
Yin, Q1
Xu, GL1
Zhu, WS2
Zhang, RL1
Ma, MM1
Liu, WH1
Liu, XF1
Cai, X1
Wei, T1
Li, G1
Chen, J2
Xu, Z2
Ding, N1
Peng, L1
Zhang, C1
Shao, Y1
Bath, PM7
Woodhouse, LJ3
Appleton, JP2
Beridze, M2
Christensen, H2
Dineen, RA2
Duley, L2
England, TJ2
Flaherty, K2
Havard, D1
Heptinstall, S3
James, M2
Krishnan, K2
Markus, HS3
Montgomery, AA1
Pocock, SJ1
Randall, M1
Ranta, A2
Robinson, TG2
Scutt, P2
Venables, GS2
Sprigg, N3
Cappellari, M1
Turcato, G1
Forlivesi, S1
Zivelonghi, C1
Bovi, P1
Bonetti, B1
Toni, D3
Nam, YH1
Brensinger, CM2
Bilker, WB2
Leonard, CE2
Kasner, SE2
Grosser, T1
Li, X3
Hennessy, S2
Easton, JD5
Farrant, M1
Barsan, W1
Conwit, RA1
Elm, JJ1
Kim, AS1
Lindblad, AS1
Palesch, YY1
Lin, J5
Han, Z2
Wang, C5
Yi, X5
Chai, Z2
Zhou, Q4
Huang, R1
Kim, JT1
Choi, KH1
Park, MS1
Lee, JS2
Saver, JL4
Cho, KH2
Kleiman, NS1
Wu, Z1
Liu, AF1
Zhou, J1
Wang, K1
Li, C2
Qiu, H1
Jiang, WJ1
Chiba, T1
Setta, K1
Shimada, Y1
Yoshida, J1
Fujimoto, K1
Tsutsui, S1
Yoshida, K1
Kobayashi, M1
Kubo, Y1
Fujiwara, S1
Terasaki, K1
Ogasawara, K1
Hankey, GJ6
Sychev, DA1
Shprakh, VV1
Kitaeva, EY1
Mirzaev, KB1
Mickhalevich, IM1
Wiśniewski, A1
Sikora, J1
Filipska, K1
Kozera, G1
Hong, JM1
Shin, DH1
Lim, YA1
Joo, IS1
Patti, G1
Tomai, F1
Melfi, R1
Ricottini, E1
Macrì, M1
Sedati, P1
Giardina, A1
Aurigemma, C1
Leporace, M1
D'Ambrosio, A1
Di Sciascio, G1
Dunn, SP1
Steinhubl, SR2
Bauer, D2
Charnigo, RJ1
Berger, PB2
Topol, EJ6
Leung, LY1
Albright, KC1
Boehme, AK1
Tarsia, J1
Shah, KR1
Siegler, JE1
Jones, EM1
Pletsch, GR1
Beasley, TM1
Martin-Schild, S1
Maruyama, H3
Fukuoka, T3
Deguchi, I3
Ohe, Y2
Nagoya, H2
Kato, Y3
Horiuchi, Y3
Hayashi, T2
Tanahashi, N3
Sorkin, GC1
Dumont, TM1
Wach, MM1
Eller, JL1
Mokin, M1
Natarajan, SK2
Baxter, MS1
Snyder, KV2
Levy, EI2
Hopkins, LN2
Siddiqui, AH2
Beynon, C1
Sakowitz, OW1
Unterberg, AW1
Liang, ZY1
Han, YL1
Zhang, XL1
Li, Y1
Yan, CH1
Kang, J1
Park, KM1
Kim, SE2
Shin, KJ1
Park, J1
Kim, HC1
Mun, CW1
Ha, SY1
Webster, CM1
Hokari, M1
McManus, A1
Tang, XN1
Ma, H1
Kacimi, R1
Yenari, MA1
Jastrzębska, M1
Chełstowski, K1
Wódecka, A1
Siennicka, A1
Clark, J1
Nowacki, P1
Lee, M2
Hong, KS2
Rao, NM2
Wu, YL2
Ovbiagele, B4
Nakagawa, I1
Wada, T1
Park, HS1
Nishimura, F1
Yamada, S1
Nakagawa, H1
Kichikawa, K1
Nakase, H1
Ferreiro, JL1
Bhatt, DL8
Ueno, M1
Angiolillo, DJ1
Nomani, F1
Kamal, AK3
Bekbosynov, AZh1
Castilla-Guerra, L1
Fernandez-Moreno, Mdel C1
Navas-Alcantara, MS1
Jimenez-Gonzalo, F1
Nagamine, Y1
Sano, H1
Kohriyama, T1
Mihara, C1
Yokoyama, T1
Torii, T1
Yamada, A1
Takamatsu, K1
Ota, T1
Noda, K1
Kataoka, S1
Ito, H2
Nomura, E1
Ohtsuki, T1
Aoki, S1
Nezu, T1
Takeda, I1
Mukai, T1
Hosomi, N1
Matsumoto, M2
Chen, CY1
Lee, KT1
Lee, CT1
Lai, WT1
Huang, YB1
Sandercock, PA1
Counsell, C1
Tseng, MC1
Cecconi, E1
Amarenco, P2
Davis, S1
Jones, EF1
Cohen, AA1
Heiss, WD1
Kaste, M3
Laouénan, C1
Young, D1
Macleod, M1
Donnan, GA3
Siepmann, T1
Heinke, D1
Kepplinger, J1
Barlinn, K1
Gehrisch, S1
Grählert, X1
Schwanebeck, U1
Reichmann, H1
Puetz, V1
Bodechtel, U1
Gahn, G2
Meng, H1
Xu, L1
Liu, J3
Kong, D1
Chen, P1
Gong, X1
Bai, J1
Zou, F1
Yang, Z2
Eikelboom, JW3
Kashiwazaki, D1
Kuwayama, N1
Akioka, N1
Hayakawa, Y1
Kuroda, S1
Isshiki, T1
Kimura, T1
Ogawa, H1
Yokoi, H1
Nanto, S1
Takayama, M1
Kitagawa, K1
Nishikawa, M1
Miyazaki, S1
Ikeda, Y2
Nakamura, M1
Saito, S1
Zhang, S1
Lai, X1
Li, W2
Xiong, Z1
Xu, A2
Huang, L1
Lee, HC1
Lee, JD1
Chang, KC1
Wu, CY1
Lee, TH1
Wang, HH1
Toyoda, K1
Uchiyama, S5
Hoshino, H1
Kimura, K1
Origasa, H1
Naritomi, H1
Minematsu, K1
Yamaguchi, T1
Qiu, LN2
Sun, Y1
Wang, L3
Han, RF2
Xia, XS2
Jeong, TD1
Kim, SM1
Kim, HJ1
Lee, W1
Kwon, SU2
Min, WK1
Kang, DW2
Chun, S1
Robson, K1
Dineen, R1
Pocock, S2
Flockhart, DA1
Freeman, CP1
Kimmel, SE1
Liu, F1
Tantry, US1
Gurbel, PA1
Yang, J1
Zhou, JS1
Zhao, YX1
Yang, ZH1
Zhao, HD1
Zhang, YD1
Zou, JJ1
Blann, AD1
Skjøth, F1
Rasmussen, LH1
Larsen, TB1
Lip, GY2
Asai, T1
Miyachi, S1
Izumi, T1
Matsubara, N1
Haraguchi, K1
Yamanouchi, T1
Ota, K1
Shintai, K1
Tajima, H1
Wakabayashi, T1
Su, Y1
Cheng, X1
Dong, Q3
Han, Y2
Lv, HH2
Liu, X3
Yang, XL2
Li, SX2
Wu, S2
Jiang, JM2
Luo, Z2
Zhu, DS1
Zheng, Y1
Guan, YT2
Xu, JF2
Flechtenmacher, N1
Kämmerer, F1
Dittmer, R1
Budde, U1
Michels, P1
Röther, J2
Eckert, B1
Lin, M2
Todaro, M1
Chan, J1
Churilov, L1
Ramdave, S1
Mitchell, PJ1
Dowling, RJ1
Kwan, P1
Yan, B1
Fabiaña, N1
Ramaswami, AP1
Ang, ES1
De Silva, DA1
Zheng, SL1
Li, L1
An, LX1
Christiansen, CB1
Pallisgaard, J1
Gerds, TA1
Olesen, JB1
Jørgensen, ME1
Numé, AK1
Carlson, N1
Kristensen, SL1
Gislason, G1
Torp-Pedersen, C2
Sternberg, Z2
Chichelli, T2
Sternberg, D1
Sawyer, R1
Ching, M2
Janicke, D2
Ambrus, JL1
Yu, J1
Munschauer, F1
Fang, L1
Zhao, Y1
Wang, N1
Mizuma, A1
Iijima, K1
Kohara, S1
Shimizu, M1
Imazeki, R1
Uesugi, T1
Ohnuki, Y1
Takizawa, S1
Kim, YJ1
Seo, WK1
Yu, S2
Oh, SH1
Kim, YN1
Tziomalos, K1
Giampatzis, V1
Bouziana, SD1
Spanou, M1
Kostaki, S1
Papadopoulou, M1
Angelopoulou, SM1
Tsopozidi, M1
Savopoulos, C1
Hatzitolios, AI1
Murphy, SJ1
Coughlan, CA1
Tobin, O1
Kinsella, J1
Lonergan, R1
Gutkin, M1
McCabe, DJ2
Komosa, A1
Siller-Matula, JM1
Lesiak, M1
Michalak, M1
Kowal, J1
Mączyński, M1
Siniawski, A1
Mularek-Kubzdela, T1
Wiśniewski, S1
Grajek, S1
Chin, CT1
Neely, B1
Magnus Ohman, E1
Armstrong, PW1
Corbalán, R1
White, HD2
Prabhakaran, D1
Winters, KJ1
Fox, KA3
Roe, MT1
Gallego-Fabrega, C1
Carrera, C1
Reny, JL1
Fontana, P1
Slowik, A1
Pera, J1
Pezzini, A1
Serrano-Heras, G1
Segura, T1
Martí-Fàbregas, J1
Muiño, E1
Cullell, N1
Montaner, J1
Krupinski, J1
Fernandez-Cadenas, I1
Zhu, WY1
Zhao, T1
Xiong, XY1
Li, J1
Zhou, Y1
Gong, ZL1
Cheng, SY1
Liu, Y1
Shuai, J1
Yang, QW1
Davis, K1
Dietrich, E1
Liu, P1
Fu, C1
Chen, Y1
Domanski, MJ1
Dillinger, JG1
Saeed, A1
Spagnoli, V1
Sollier, CB1
Sideris, G1
Silberman, SM1
Voicu, S1
Drouet, L2
Henry, P1
Lee, SH1
Kim, EG1
Chang, DI1
Rha, JH1
Bae, HJ1
Lee, KB1
Kim, DE1
Park, JM1
Kim, HY1
Cha, JK4
Yu, KH1
Lee, YS1
Lee, SJ1
Choi, JC1
Cho, YJ1
Kim, GM1
Sohn, SI1
Park, KY1
Sohn, CH1
Lee, J1
Yoon, BW2
Deng, QQ1
Tang, J1
Chen, C2
Markus, H1
Huang, YN1
Zhao, H1
Ratanakorn, D1
Wong, KS1
Fu, JH1
Cheng, W2
Chi, L1
He, Y1
Cai, H1
Zhou, G1
Zhang, Z1
Moris, D1
Bakoyiannis, C1
Karaolanis, G1
Georgopoulos, S1
Sawlani, NN1
Harrington, RA1
Steg, PG2
Gibson, CM1
Hamm, CW2
Price, MJ1
Prats, J1
Deliargyris, EN1
Mahaffey, KW2
Zhang, Q1
Song, H1
Hou, C1
Cao, Q1
Huang, X1
Feng, W1
Wang, M1
Ji, X1
Chen, YT1
Chen, HT1
Hsu, CY1
Chao, PW1
Kuo, SC1
Ou, SM1
Shih, CJ1
Li, XG1
Ma, N1
Sun, SS1
Yang, X1
Miao, ZR1
Zhao, ZG1
Belvís, R1
Pagonabarraga, J1
Santamaría, A1
Kulisevsky, J1
Sztriha, LK1
Vécsei, L1
Albers, GW2
Sacco, RL4
Teal, P2
Diener, HC7
Yusuf, S4
Cotton, D3
Ounpuu, S1
Lawton, WA1
Palesch, Y2
Martin, RH3
Bath, P2
Bornstein, N1
Chan, BP1
Chen, ST1
Cunha, L1
Dahlöf, B1
De Keyser, J1
Estol, C2
Gorelick, P2
Gu, V1
Hermansson, K2
Hilbrich, L1
Lu, C1
Machnig, T1
Pais, P2
Roberts, R2
Skvortsova, V1
Vandermaelen, C1
Voigt, T1
Weber, M1
Vande Griend, JP1
Saseen, JJ1
Suri, MF1
Hussein, HM1
Abdelmoula, MM1
Divani, AA1
Qureshi, AI3
Jeon, HW1
Kang, MJ1
Minnerup, J1
Schäbitz, WR1
Hart, RG4
Hegge, KA1
Faxon, DP1
Freedman, JE1
Leys, D1
Balucani, C1
Cordonnier, C1
Biller, J1
Hermann, A1
Dzialowski, I1
Koch, R1
Beckman, JA1
Ionita, CC1
Slaviero, F1
Annes, RD1
Frighetto, L1
Schirmer, LM1
Vanzin, JR1
Fröhlich, AC1
Ferraz, J1
Azambuja, ND1
Bal Dit Sollier, C1
Crassard, I1
Simoneau, G1
Bergmann, JF1
Bousser, MG1
Gomez, CR1
Hashimoto, A1
Matsumoto, Y1
Yao, H1
Miyakoda, G1
Pinto, A1
Di Raimondo, D1
Tuttolomondo, A1
Di Sciacca, R1
Arnao, V1
La Placa, S1
Milio, G1
Miceli, S1
Licata, G1
Meyer, D1
Serebruany, V1
Cherala, G1
Williams, C1
Surigin, S1
Booze, C1
Kuliczkowski, W1
Atar, D1
Diedler, J1
Ahmed, N2
Sykora, M1
Uyttenboogaart, M1
Overgaard, K2
Luijckx, GJ1
Soinne, L1
Ford, GA2
Lees, KR2
Wahlgren, N2
Ringleb, P1
Laufs, U1
Hoppe, UC1
Rosenkranz, S1
Kirchhof, P1
Böhm, M1
Endres, M1
Grond, M1
Hacke, W8
Meinertz, T1
Ringelstein, EB2
Dichgans, M1
Sacco, R1
Burke, JP1
Sander, S1
Shah, H1
Zarotsky, V1
Henk, H1
Mandalà, M1
Rufa, A1
Cerase, A1
Bracco, S1
Galluzzi, P1
Venturi, C1
Nuti, D1
Weise, J1
Reinhöfer, M1
Witte, OW1
Mayer, TE1
Menon, BK1
Frankel, MR1
Liang, L1
Labresh, KA1
Ellrodt, G1
Hernandez, AF1
Fonarow, GC1
Schwamm, LH2
Smith, EE1
Lee, SP3
Suh, JW3
Park, KW4
Lee, HY2
Kang, HJ2
Koo, BK2
Chae, IH3
Choi, DJ2
Rha, SW3
Bae, JW3
Cho, MC3
Kwon, TG2
Bae, JH3
Kim, HS3
Hansen, ML1
Sørensen, R1
Clausen, MT1
Fog-Petersen, ML1
Raunsø, J1
Gadsbøll, N1
Gislason, GH1
Folke, F1
Andersen, SS1
Schramm, TK1
Abildstrøm, SZ1
Poulsen, HE1
Køber, L1
Christoforidis, GA1
Rink, C1
Kontzialis, MS1
Mohammad, Y1
Koch, RM1
Abduljalil, AM1
Bergdall, VK1
Roy, S1
Khanna, S1
Slivka, AP1
Knopp, MV1
Sen, CK1
Sakata, T1
Kario, K1
Mas, JL2
Brennan, D1
Mak, KH2
Fedorov, A1
Chibisova, Y1
Szymaszek, A1
Alexandrov, M1
Gall, C1
Sabel, BA1
Furuya, D1
Takeda, H1
Dembo, T1
Cho, YS1
Youn, TJ1
Khan, M1
Gaillard, R1
Mir, O1
Gonzenbach, RR1
Taegtmeyer, AB1
Luft, A1
Russmann, S1
Sibbing, D1
Byrne, RA1
Kastrati, A1
Mono, ML1
Geister, L1
Galimanis, A1
Jung, S1
Praz, F1
Arnold, M1
Fischer, U1
Wolff, S1
Findling, O1
Windecker, S1
Wahl, A1
Meier, B1
Mattle, HP2
Nedeltchev, K1
Duelsner, A1
Gatzke, N1
Glaser, J1
Hillmeister, P1
Li, M1
Lee, EJ1
Lehmann, K1
Urban, D1
Meyborg, H1
Stawowy, P1
Busjahn, A1
Nagorka, S1
Persson, AB1
Buschmann, IR1
Greenhalgh, J1
Bagust, A1
Boland, A1
Martin Saborido, C1
Oyee, J1
Blundell, M1
Dundar, Y1
Dickson, R1
Proudlove, C1
Fisher, M2
Vinisko, R1
Meves, SH1
Overbeck, U1
Endres, HG1
Krogias, C1
Neubauer, H1
Sawyer, RN1
Li, F1
Radovic, V1
Mehta, B1
Farooq, O1
Munschauer, FE1
Weber, R1
Weimar, C1
Wanke, I1
Möller-Hartmann, C1
Gizewski, ER1
Blatchford, J1
Demchuk, AM1
Forsting, M1
Warach, S1
Diehl, A1
Acelajado, MC1
Oparil, S1
Geeganage, CM1
Algra, A2
Dengler, R1
Bath, MW1
Wiesemann, S1
Passlick, B1
Mazya, M1
Egido, JA1
Mikulik, R1
Agarwal, S1
Hachamovitch, R1
Menon, V1
Soo, YO1
Siu, DY1
Abrigo, J1
Ng, N1
Ahuja, AT1
Wong, LK1
Leung, TW1
James, SK1
Storey, RF1
Khurmi, NS1
Husted, S1
Keltai, M1
Maya, J1
Morais, J1
Lopes, RD1
Nicolau, JC1
Raev, D1
Lopez-Sendon, JL1
Stevens, SR1
Becker, RC1
Depta, JP1
Fowler, J1
Novak, E1
Katzan, I2
Bakdash, S1
Kottke-Marchant, K1
Rose, DZ1
Koch, S1
Reyes-Iglesias, Y1
Yavagal, DR1
Rossen, JD1
Chalouhi, N1
Wassef, SN1
Thomas, J1
Abel, TJ1
Jabbour, PM1
Kung, DK1
Hasan, DM1
Kinsella, JA1
Tobin, WO1
Cox, D1
Coughlan, T1
Collins, R1
O'Neill, D1
Murphy, RP1
Coppens, M1
Dorian, P1
Shestakovska, O1
Connolly, SJ1
Wadiwala, MF1
Shevelev, VI1
Kanorsky, SG1
Michel, P1
Thomson, RM1
Anderson, DC1
Musolino, R1
La Spina, P1
Granata, A1
Gallitto, G1
Leggiadro, N1
Carerj, S1
Manganaro, A1
Tripodi, F1
Epifanio, A1
Gangemi, S1
Di Perri, R1
Grau, AJ2
Reiners, S1
Lichy, C2
Buggle, F2
Ruf, A1
Jeong, MH1
Lee, KM1
Bae, HR2
Lim, YJ1
Cheon, SM1
Yamazaki, M2
Ringleb, PA3
Hirsch, AT2
Jo, WS1
Shin, HC1
Ho, JM1
Kim, JW1
Haerten, K1
Krabbe, C1
Raiber, M1
Boddy, AW1
Dukovic, DA1
Brandt, T1
Schellinger, PD3
Jüttler, E1
Meyding-Lamadé, UK1
Schwark, C2
Pongrácz, E1
Lewis, SC1
Warlow, CP1
Skvortsova, VI2
Shamalov, NA1
Moussouttas, M1
Papamitsakis, N1
Eriksson, P1
Zhao, L2
Fletcher, S1
Weaver, C1
Leonardi-Bee, J2
May, J1
Fox, S1
Willmot, M1
Heptinstal, S1
Schwaninger, M1
Ziegler, S1
Schillinger, M1
Funk, M1
Felber, K1
Exner, M1
Mlekusch, W1
Sabeti, S1
Amighi, J1
Minar, E1
Brunner, M1
Müller, M1
Mannhalter, C1
Tonarelli, SB1
Pearce, LA1
Lee, JH1
Park, SY1
Lee, WS1
Hong, KW1
Lemenev, VL1
Akhmetov, VV1
Alekseeva, GS1
Stakhovskaia, LV1
Gutsaliuk, AG1
Serebruany, VL1
Malinin, AI1
Ziai, W1
Pokov, AN1
Alberts, MJ2
Hanley, DF1
Black, HR1
Boden, WE1
Cacoub, P1
Cohen, EA1
Creager, MA1
Flather, MD1
Haffner, SM1
Montalescot, G1
Pearson, TA1
Weber, MA1
Booth, J1
Kawaguchi, S1
Ishizashi, H1
Yagi, H1
Iida, J1
Sakaki, T1
Fujimura, Y1
Szapáry, L2
Gray, L1
Weaver, CS1
Soman, T1
Rafay, MF1
Hune, S1
Allen, A1
MacGregor, D1
deVeber, G1
Kirmani, JF1
Safdar, A1
Ahmed, S1
Sayed, MA1
Pande, RU1
Ferguson, R1
Hershey, LA2
Qazi, KJ1
Kirichenko, AA1
Wallaschofski, H1
Lohmann, T1
Hild, E1
Kobsar, A1
Siegemund, A1
Spilcke-Liss, E1
Hentschel, B1
Stumpf, C1
Daniel, WG1
Garlichs, CD1
Eigenthaler, M1
Késmárky, G1
Fehér, G2
Koltai, K1
Horváth, B2
Tóth, K2
Onizuka, M1
Kazekawa, K1
Nagata, S1
Tsutsumi, M1
Aikawa, H1
Tomokiyo, M1
Iko, M1
Kodama, T1
Nii, K1
Matsubara, S1
Tanaka, A1
Lee, MS1
Smith, SD1
Galor, A1
Hoffman, GS1
Al-Bahrani, A1
Taha, S1
Shaath, H1
Bakhiet, M1
Papp, E1
Havasi, V1
Bene, J1
Komlosi, K1
Talian, G1
Melegh, B1
Spiesser, J1
Hakimi, Z1
Bego, G1
Carita, P1
Gabriel, S1
Emre, U1
Rantanen, K1
Tatlisumak, T1
Poulsen, TS1
Husted, SE1
Reaume, KT1
Regal, RE1
Dorsch, MP1
Adams, RJ1
Albers, G1
Benavente, O1
Furie, K1
Goldstein, LB1
Halperin, J1
Harbaugh, R1
Kelly-Hayes, M1
Kenton, EJ1
Marks, M1
Helgason, CM1
Grossi, E1
Pandey, D1
Valika, A1
Cursio, J1
Brace, LD1
Nielsen, AA1
Veien, KT1
Jørgensen, LG1
Buck, TC1
Brandslund, I1
Christensen, C1
Sokurenko, GIu1
Luk'ianov, IuV1
Parusova, EV1
Edovina, LN1
Skliut, M1
Jamieson, DG1
Mirouze, J1
Herce Muñoz, M1
Sancho Rieger, J1
López-Trigo Picho, J1
Casto, L1
Camerlingo, M1
Finazzi, G1
Censori, B1
Barbui, T1
Mamoli, A1
Iwamoto, T1
Kubo, H1
Takasaki, M1
Verry, M1
Panak, E1
Cazenave, JP1
Maruyama, S3
Handa, M1
Fukuyama, M1
Itagaki, I1
Solomon, DH1
Weisberg, LA1
Bruno, A1
Díaz-Marín, C1
Matías-Guiu, J1
Rey, A1
Aguilar, M1
Bonaventura, I1
Martínez, I1
Quintana, S1
Noble, S1
Goa, KL1
Bendixen, BH1
Adams, HP1
Violi, F1
Toplak, H1
Bahadori, B1
Wascher, TC1
Davie, AP1
Love, MP1
López-Domínguez, JM1
Casado-Chocán, JL1
Blanco-Ollero, A1
Rodríguez-Verdugo, M1
Robledo-Strauss, A1
Díaz-Espejo, C1
Rosa, A1
Canaple, S1
Orberk, E1
Zarranz Imirizaldu, JJ1
Noth, J1
Koudstaal, PJ1
van Gijn, J1
Pellegrino, TR1
Ferguson, JJ1
Gonzalez, ER1
Kannel, WB1
Olin, JW1
Raps, EC1
Boysen, G1
Akyuz, A1
Bolayir, E1
Dener, S1
Topalkara, K1
Topaktas, S1
Zusman, RM1
Chesebro, JH1
Comerota, A1
Hartmann, JR1
Massin, EK1
Raps, E1
Wolf, PA1
Holm, J1
Hillarp, A1
Erhardt, L1
Berntorp, E1
Caro, JJ1
Migliaccio-Walle, K1
Carlsson, J1
Miketic, S1
Bätge, R1
Riedel, P1
Rahlf, G1
Tebbe, U1
Sudlow, CL1
Dunbabin, DW1
Mesec, A1
Rot, U1
Grad, A1
Jackson, G1
Shirakura, S1
Sano, J1
Karasawa, A1
Kubo, K1
Fogelholm, R1
Riekkinen, P1
Sivenius, J1
Ketsa-Ard, K1
Poungvarin, N1
Juengchareon, M1
Jarerat, S1
Kittigul, L1
Joseph, R1
Han, E1
Grunfeld, S1
Robertson, W1
Ciuffetti, G1
Aisa, G1
Mercuri, M1
Lombardini, R1
Paltriccia, R1
Neri, C1
Senin, U1
Sone, R1
Nagayama, T2
Shibagaki, Y1
Kobayashi, I2
Kusakabe, K1
Tsutsumi, Y1
Manopulo, R1
Sturani, A1
Insarda, P1
Jaffe, DF1
Greenough, PG1
Yang, SL1

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705]2,927 participants (Actual)Observational2019-09-20Completed
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589]Phase 35,100 participants (Actual)Interventional2009-12-31Completed
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984]Phase 260 participants (Anticipated)Interventional2021-08-01Recruiting
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862]350 participants (Anticipated)Interventional2023-04-24Recruiting
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081]1,067 participants (Anticipated)Observational [Patient Registry]2021-02-03Recruiting
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889]Phase 3516 participants (Anticipated)Interventional2023-11-09Recruiting
Efficacy of Two Different Pre-Intervention Therapeutic Strategies With Clopidogrel and Atorvastatin for the Prevention of Cerebral Damage During Carotid Artery Stenting. Armyda-Caro Randomized Trial.[NCT01572623]Phase 4150 participants (Anticipated)Interventional2011-07-31Recruiting
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248]Phase 3350 participants (Actual)Interventional2002-02-28Completed
Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370]Phase 41,884 participants (Actual)Interventional2013-12-13Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping[NCT01174693]Phase 4795 participants (Actual)Interventional2010-03-31Completed
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998]Phase 39,326 participants (Actual)Interventional2008-06-30Completed
COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268]Phase 4358 participants (Actual)Interventional2008-12-31Completed
The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872]2,000 participants (Anticipated)Observational2013-05-31Enrolling by invitation
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828]Phase 4960 participants (Actual)Interventional2006-11-30Completed
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574]84 participants (Actual)Observational2019-02-26Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995]Phase 4140 participants (Actual)Interventional2012-02-01Completed
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]142 participants (Actual)Interventional2019-11-20Completed
Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361]159 participants (Actual)Observational2010-07-31Completed
Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744]3,400 participants (Anticipated)Interventional2018-01-31Not yet recruiting
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]Phase 318,624 participants (Actual)Interventional2006-10-31Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261]Phase 41,001 participants (Actual)Interventional2003-04-30Completed
Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982]1,500 participants (Actual)Observational2012-10-31Completed
Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414]Phase 255 participants (Actual)Interventional2015-02-28Completed
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]100 participants (Anticipated)Observational2021-03-10Not yet recruiting
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke

The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.61
Prasugrel: 75 Years of Age or Older27.04
Clopidogrel: <75 Years of Age11.12
Clopidogrel: 75 Years of Age or Older26.83

Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.06
Prasugrel: 75 Years of Age or Older24.64
Clopidogrel: <75 Years of Age10.96
Clopidogrel: 75 Years of Age or Older24.13

Percentage of Participants With a Composite Endpoint of CV Death and MI

The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age9.61
Prasugrel: 75 Years of Age or Older22.53
Clopidogrel: <75 Years of Age10.21
Clopidogrel: 75 Years of Age or Older22.69

Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA)

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age12.13
Prasugrel: 75 Years of Age or Older26.27
Clopidogrel: <75 Years of Age12.83
Clopidogrel: 75 Years of Age or Older25.67

Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP)

Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months

,,,
Interventionpicograms per milliliter (pg/mL) (Geometric Mean)
Day 306 Months (n=725, 125, 701, 174)
Clopidogrel: <75 Years of Age319.345250.982
Clopidogrel: 75 Years of Age or Older951.359722.750
Prasugrel: <75 Years of Age313.494253.434
Prasugrel: 75 Years of Age or Older1082.396770.132

Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6

,,,
Interventionmilligrams per liter (mg/L) (Geometric Mean)
Day 306 Months (n=755, 143, 745, 178)
Clopidogrel: <75 Years of Age2.2872.149
Clopidogrel: 75 Years of Age or Older2.2261.543
Prasugrel: <75 Years of Age2.3302.272
Prasugrel: 75 Years of Age or Older2.4411.593

Economic and Quality of Life Outcomes

Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)

,
Interventionunits on a scale (Mean)
Baseline, physical limitationsBaseline, angina frequency24 Months, physical limitations (n=420, 412)24 Months, angina frequency (n=420, 412)
Clopidogrel67.073.174.589.5
Prasugrel67.873.675.189.7

Genotyping Related to Drug Metabolism

Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline

,,,
Interventionpercentage participants with geneotype (Number)
UM, *1/*17UM, *17/*17EM (non-UM), *1/*1IM, *1/*2IM, *1/*3IM, *1/*4IM, *1/*6IM, *1/*8PM, *2/*2PM, *2/*3PM, *2/*4PM, *2/*6PM, *2/*8PM, *3/*3UNK, *1/*10UNK, *1/*13UNK, *1/*9UNK, *1/*9, *9/*17UNK, *13/*17UNK, *2/*13UNK, *2/*17UNK, *2/*9UNK, *3/*17UNK, *4/*17UNK, *4/*9UNK, *6/*17UNK, *8/*17UNK, *9/*17UNK, Undefined genotype
Clopidogrel: <75 Years of Age25.15.435.719.80.50.10.00.44.30.30.20.00.00.20.10.00.00.00.00.06.80.10.00.20.00.00.10.00.5
Clopidogrel: 75 Years of Age or Older21.84.341.219.70.60.30.20.33.80.30.20.00.00.00.00.00.00.00.00.06.20.00.30.00.00.20.00.00.6
Prasugrel: <75 Years of Age24.05.138.818.60.80.40.00.13.90.30.00.00.00.00.00.00.10.00.00.06.30.00.10.20.00.00.20.00.7
Prasugrel: 75 Years of Age or Older25.03.642.118.30.60.00.20.52.20.20.20.00.00.00.00.20.20.00.00.06.10.00.00.20.00.00.00.00.6

Platelet Aggregation Measures

Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months

,,,
InterventionP2Y12 Reaction Units (PRU) (Least Squares Mean)
Day 30Month 12 (n=386, 76, 400, 103)
Clopidogrel: <75 Years of Age193.489199.003
Clopidogrel: 75 Years of Age or Older200.285181.360
Prasugrel: <75 Years of Age93.28094.529
Prasugrel: 75 Years of Age or Older151.872135.096

Summary of All Deaths

All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

,,,
Interventionparticipants (Number)
Congestive Heart FailureCardiogenic ShockCardiac RuptureMyocardial InfarctionDysrhythmiaStent ThrombosisDirectly Related to Revascularization-CABG or PCIIntracranial HemorrhageNon-Hemorrhagic StrokeSudden death due to cardiovascular eventPulmonary EmbolismStroke, unknown typeOther Cardiovascular EventCardiovascular event, unknown typeAccidentalTraumaHemorrhage, not intracranialInfectionMalignancySuicideOther Non-Cardiovascular eventCause unknown (nonadjudicated event)
Clopidogrel: <75 Years of Age13100246014470200451001614080
Clopidogrel: 75 Years of Age or Older2390213011343101451141711060
Prasugrel: <75 Years of Age1080165012475006401211414180
Prasugrel: 75 Years of Age or Older214124201143911141031217041

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

Area Under Curve of Serial Cardiac Biomarkers

An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionHours*ng/ml (Median)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)38.092.7
Control C2 (Low Platelet Reactivity - no Tirofiban)121.4185.6
Group A (High Platelet Reactivity - Tirofiban)197.2252.5

Percentage of Participants With Periprocedural Myonecrosis

"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionParticipants (Count of Participants)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)1510
Control C2 (Low Platelet Reactivity - no Tirofiban)2625
Group A (High Platelet Reactivity - Tirofiban)1611

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR901
CLOPIDOGREL1065

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR1290
CLOPIDOGREL1456

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR569
CLOPIDOGREL668

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR864
CLOPIDOGREL1014

Participants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR961
CLOPIDOGREL929

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR619
CLOPIDOGREL654

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR329
CLOPIDOGREL341

Participants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR399
CLOPIDOGREL506

Participants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR353
CLOPIDOGREL442

Participants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR1339
CLOPIDOGREL1215

Participants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR504
CLOPIDOGREL593

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR362
CLOPIDOGREL306

Participants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR235
CLOPIDOGREL180

Participants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR125
CLOPIDOGREL106

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR21
CLOPIDOGREL16

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR84
CLOPIDOGREL51

Percentage Leukocyte-Platelet Aggregate

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline14.06
Placebo Follow up13.84
Aspirin Baseline11.18
Aspirin Randomization12.11
Clopidogrel Baseline13.06
Clopidogrel Randomization12.29

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline15.53
Placebo Follow up15.43
Aspirin Baseline13.15
Aspirin Follow up14.96
Clopidogrel Baseline16.03
Clopidogrel Follow up14.85

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With ADP 5μM for 5 Min

(NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min

The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline72.35
Placebo Follow up79.11
Aspirin Baseline72.79
Aspirin Randomization26.77
Clopidogrel Baseline71.07
Clopidogrel Randomization65.00

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Reviews

50 reviews available for ticlopidine and Cerebral Ischemia

ArticleYear
[Optimal antiplatelet strategy in patients with high-risk transient ischemic attack and minor ischemic stroke].
    Zhonghua nei ke za zhi, 2019, Sep-01, Volume: 58, Issue:9

    Topics: Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticlopi

2019
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.
    Journal of the neurological sciences, 2017, May-15, Volume: 376

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation

2017
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
    Journal of the American Heart Association, 2013, Jan-15, Volume: 2, Issue:1

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Cytochrom

2013
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
    Annals of internal medicine, 2013, Oct-01, Volume: 159, Issue:7

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human

2013
Oral antiplatelet therapy for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2014, Mar-26, Issue:3

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle

2014
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M

2015
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre

2015
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug

2015
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:11

    Topics: Antiplatyhelmintic Agents; Aspirin; Brain Ischemia; Clopidogrel; Evidence-Based Medicine; Humans; St

2015
Clopidogrel in secondary ischemic stroke prevention.
    Recent patents on cardiovascular drug discovery, 2008, Volume: 3, Issue:2

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Evidence-

2008
Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Pharmacotherapy, 2008, Volume: 28, Issue:10

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat

2008
Multifunctional actions of approved and candidate stroke drugs.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009, Volume: 6, Issue:1

    Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha

2009
What's new in stroke? The top 10 studies of 2006-2008. Part I.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:11

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
Antiplatelet agents for prevention of recurrent ischemic stroke.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2009, Volume: 62, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic

2009
Antiplatelet drugs for ischemic stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 27 Suppl 1

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination;

2009
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic;

2009
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy,

2009
Antiplatelet treatment in ischemic stroke treatment.
    Current topics in medicinal chemistry, 2009, Volume: 9, Issue:14

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine

2009
Antiplatelets and stroke outcomes: state of the science.
    Critical care nursing clinics of North America, 2009, Volume: 21, Issue:4

    Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy

2009
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop

2011
Role of platelet function testing in clinical practice: current concepts and future perspectives.
    Current drug targets, 2011, Volume: 12, Issue:12

    Topics: Acute Coronary Syndrome; Biotransformation; Brain Ischemia; Clopidogrel; Drug Monitoring; Drug Resis

2011
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac

2011
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
    Stroke, 2012, Volume: 43, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab

2012
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel;

2012
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
    Current pharmaceutical design, 2013, Volume: 19, Issue:21

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S

2013
Aspirin and clopidogrel for prevention of ischemic stroke.
    Current neurology and neuroscience reports, 2013, Volume: 13, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platel

2013
[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
    Fortschritte der Neurologie-Psychiatrie, 2004, Volume: 72, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relation

2004
Combination antiplatelet agents in ischemic cerebrovascular disease.
    The Mount Sinai journal of medicine, New York, 2005, Volume: 72, Issue:1

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2005
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans

2005
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Neurology, 2005, Apr-12, Volume: 64, Issue:7

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At

2005
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
    Archives of neurology, 2006, Volume: 63, Issue:1

    Topics: Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Platelet A

2006
[Mechanism of action and clinical use of ticlopidine].
    Kardiologiia, 2006, Volume: 46, Issue:4

    Topics: Arterial Occlusive Diseases; Brain Ischemia; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Myo

2006
Antithrombotic treatment in the prevention of ischemic stroke.
    Current drug targets, 2007, Volume: 8, Issue:7

    Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Clopidogrel; Fibrinolytic Agents; Humans; Platele

2007
The PRoFESS trial: future impact on secondary stroke prevention.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2007
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron

2008
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
    Current cardiology reports, 2008, Volume: 10, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi

2008
Antiplatelet therapy in the prevention of ischaemic stroke.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Platele

1994
Antithrombotic therapies for stroke prevention.
    Current opinion in neurology, 1994, Volume: 7, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti

1994
[Therapy and prevention of cerebral ischemia].
    Therapeutische Umschau. Revue therapeutique, 1996, Volume: 53, Issue:7

    Topics: Angioplasty, Balloon; Anticoagulants; Brain Ischemia; Combined Modality Therapy; Drug Therapy, Combi

1996
Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.
    Drugs & aging, 1996, Volume: 8, Issue:3

    Topics: Brain Ischemia; Cerebrovascular Disorders; Drug Interactions; Humans; Platelet Aggregation Inhibitor

1996
Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke.
    European neurology, 1996, Volume: 36, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregation Inhibi

1996
[Antithrombotic therapy after cerebral ischemia].
    Fortschritte der Neurologie-Psychiatrie, 1997, Volume: 65, Issue:9

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy,

1997
[Anti-aggregation therapy for prevention of cerebral ischemic stroke: a risk benefit analysis].
    Medicina clinica, 1997, Dec-06, Volume: 109, Issue:20

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Risk; Ti

1997
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel

1998
Anticoagulants and antiplatelet agents in acute ischemic stroke.
    Virginia medical quarterly : VMQ, 1998,Spring, Volume: 125, Issue:2

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials a

1998
Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
    Clinical cardiology, 1999, Volume: 22, Issue:9

    Topics: Algorithms; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Critic

1999
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
    Stroke, 2000, Volume: 31, Issue:7

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2000
[The use of drugs that affect thrombocytes in cerebral ischemia].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:11

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Female; Humans; Male; Ticlopidine

1990

Trials

59 trials available for ticlopidine and Cerebral Ischemia

ArticleYear
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
    Neurology, 2017, May-16, Volume: 88, Issue:20

    Topics: Aspirin; Brain Ischemia; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrino

2017
Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
    Stroke, 2017, Volume: 48, Issue:11

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Ischemia; Clopidogrel; Double-Bl

2017
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Journal of neurology, 2018, Volume: 265, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem

2018
Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia.
    Thrombosis research, 2013, Volume: 131, Issue:4

    Topics: Acute Disease; Alleles; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450

2013
Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting
    Journal of the American College of Cardiology, 2013, Apr-02, Volume: 61, Issue:13

    Topics: Aged; Angioplasty, Balloon; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Carotid Artery D

2013
Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clopidogrel;

2013
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
    Journal of the American College of Cardiology, 2014, Mar-04, Volume: 63, Issue:8

    Topics: Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Female; Humans; Male; Risk Factors; Single-Bl

2014
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
    Stroke, 2014, Volume: 45, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia;

2014
Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:5

    Topics: Aged; Brain Ischemia; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP3A; Double-Blind Method;

2014
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12

    Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP

2014
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
    BMJ open, 2014, Dec-02, Volume: 4, Issue:12

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud

2014
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation

2015
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2016, Volume: 11, Issue:4

    Topics: Brain Ischemia; Cerebral Hemorrhage; Chemoprevention; Clopidogrel; Cytochrome P-450 CYP2C19; Follow-

2016
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
    Stroke, 2016, Volume: 47, Issue:9

    Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap

2016
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
    Journal of the neurological sciences, 2016, Aug-15, Volume: 367

    Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co

2016
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
    Neurology, 2016, Oct-11, Volume: 87, Issue:15

    Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth

2016
Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:1

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male

2018
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
    International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans;

2017
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
    Neurology, 2017, Mar-14, Volume: 88, Issue:11

    Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin

2017
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
    Medical science monitor : international medical journal of experimental and clinical research, 2008, Volume: 14, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A

2008
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 28, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug

2009
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Stroke, 2010, Volume: 41, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla

2010
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
    Trials, 2010, Aug-24, Volume: 11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel

2010
Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
    International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hu

2011
Non-invasive alternating current stimulation induces recovery from stroke.
    Restorative neurology and neuroscience, 2010, Volume: 28, Issue:6

    Topics: Aged; Aphasia; Aspirin; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Electric Stimulation

2010
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:11

    Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru

2011
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
    Stroke, 2012, Volume: 43, Issue:6

    Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F

2012
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
    Stroke, 2012, Volume: 43, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel;

2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
    Circulation, 2012, Jun-12, Volume: 125, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial

2012
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre

2013
What is better antiplatelet agent to prevent recurrent stroke?
    JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2012
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
    Stroke, 2003, Volume: 34, Issue:4

    Topics: Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Clopidogrel; Cross-Ove

2003
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
    Journal of thrombosis and thrombolysis, 2002, Volume: 14, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D

2002
Leukocyte count as an independent predictor of recurrent ischemic events.
    Stroke, 2004, Volume: 35, Issue:5

    Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk

2004
Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
    Clinical hemorheology and microcirculation, 2004, Volume: 30, Issue:3-4

    Topics: Adenosine Diphosphate; Adult; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Collagen; Epinep

2004
[The results of the MATCH study evidence for advantages of Clopidogrel monotherapy as secondary prophylaxis in cerebrovascular pathology].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2004, Issue:Suppl 11

    Topics: Aged; Brain Ischemia; Clopidogrel; Disease Progression; Double-Blind Method; Female; Follow-Up Studi

2004
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
    Thrombosis and haemostasis, 2005, Volume: 93, Issue:3

    Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog

2005
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
    Stroke, 2005, Volume: 36, Issue:10

    Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Platelets; Bra

2005
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disea

2005
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
    Platelets, 2006, Volume: 17, Issue:2

    Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C

2006
Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Humans; Platelet Ag

2008
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Clinical Trials as T

1984
Shear-induced platelet aggregation in cerebral ischemia.
    Stroke, 1994, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Brain Ischemia; Cerebral Infarction;

1994
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
    Neurology, 1993, Volume: 43, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu

1993
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re

1996
The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study.
    European journal of neurology, 1999, Volume: 6, Issue:1

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combin

1999
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
    Thrombosis research, 1999, Nov-01, Volume: 96, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca

1999
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
    American heart journal, 2000, Volume: 140, Issue:1

    Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem

2000
Clinical study on antithrombotic effects of ticlopidine in ischemic stroke.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1991, Volume: 74, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Brain Ischemia; Cerebrovascular Disorders; Epopros

1991
Effect of ticlopidine and aspirin on platelet ionized calcium in ischemic stroke.
    Stroke, 1991, Volume: 22, Issue:4

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Calcium; Collagen; Humans; In Vitro Techniques; Platelet A

1991
Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study.
    Angiology, 1990, Volume: 41, Issue:7

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Double-Blind Method; Erythrocyte Deformability; Female; Fib

1990
[Ticlopidine in the prevention of cerebral ischemia. Experience with a geriatric case load].
    Minerva medica, 1988, Volume: 79, Issue:8

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clinical Trials as Topic; Double-Blind Method; Drug Evaluat

1988

Other Studies

155 other studies available for ticlopidine and Cerebral Ischemia

ArticleYear
Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients.
    BMC neurology, 2021, Oct-26, Volume: 21, Issue:1

    Topics: Brain Ischemia; Glucose; Humans; Ischemic Stroke; Platelet Aggregation; Platelet Aggregation Inhibit

2021
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
    Stroke, 2022, Volume: 53, Issue:1

    Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A

2022
Aspirin plus clopidogrel versus aspirin Mono-Therapy for ischemic stroke.
    Scandinavian cardiovascular journal : SCJ, 2020, Volume: 54, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine

2020
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
    BMJ open, 2020, 08-05, Volume: 10, Issue:8

    Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Stroke; Multicente

2020
Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports.
    The Journal of international medical research, 2020, Volume: 48, Issue:10

    Topics: Aged; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination;

2020
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged

2020
Association of measured platelet reactivity with changes in P2Y
    American heart journal, 2017, Volume: 187

    Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; M

2017
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Chi-Square Distribution; Clopidog

2017
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:10

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi

2017
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel

2017
Effects With and Without Clopidogrel Loading Treatment for Acute Ischemic Cerebrovascular Disease Patients: A Retrospective Cohort Study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Aged; Aged, 80 and over; Brain; Brain Ischemia; Clinical Decision-Making; Clopidogrel; Disease Progr

2017
Emergent loading dose of antiplatelets for stenting after IV rt-PA in acute ischemic stroke: a feasibility study.
    The International journal of neuroscience, 2018, Volume: 128, Issue:4

    Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Computed Tomography Angiogr

2018
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2017, Dec-10, Volume: 34, Issue:6

    Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Inter

2017
STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.
    Stroke, 2018, Volume: 49, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol

2018
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia;

2018
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto

2018
Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke.
    Journal of the American Heart Association, 2018, 06-01, Volume: 7, Issue:11

    Topics: Acute Disease; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Humans; Male; Pl

2018
Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting.
    JACC. Cardiovascular interventions, 2018, 07-09, Volume: 11, Issue:13

    Topics: Blood Platelets; Brain Ischemia; Drug-Eluting Stents; Humans; Stents; Stroke; Ticlopidine; Treatment

2018
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag

2019
Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:11

    Topics: Adult; Blood Flow Velocity; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Dr

2018
Prasugrel or clopidogrel for long-term secondary stroke prevention?
    The Lancet. Neurology, 2019, Volume: 18, Issue:3

    Topics: Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Strok

2019
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2019, Volume: 119, Issue:3. Vyp. 2

    Topics: Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 Enzyme System; Female;

2019
Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients.
    Neurologia i neurochirurgia polska, 2019, Volume: 53, Issue:4

    Topics: Blood Platelets; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors; Risk Factors

2019
Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7

    Topics: Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Plat

2013
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
    Journal of neurointerventional surgery, 2014, Volume: 6, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio

2014
Multiple electrode aggregometry in antiplatelet-related intracerebral haemorrhage.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2013, Volume: 20, Issue:12

    Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Humans; Male; Pla

2013
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf

2013
Isolated foot drop in acute infarction of the supplementary motor area.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:10

    Topics: Brain Ischemia; Cerebral Angiography; Cerebral Infarction; Clopidogrel; Diffusion Magnetic Resonance

2013
Microglial P2Y12 deficiency/inhibition protects against brain ischemia.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Animals; Apoptosis; Astrocytes; Brain Ischemia; CA1 Region, Hippocampal; Cell Hypoxia; Cell Movement

2013
Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:8

    Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Cholesterol, HDL; Clopido

2013
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Journal of vascular surgery, 2014, Volume: 59, Issue:3

    Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag

2014
LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this wi
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:10

    Topics: Aspirin; Brain Ischemia; Female; Humans; Ischemic Attack, Transient; Male; Ticlopidine

2013
[Combined correction of impairments of the functional state of the haemostasis system in patients with ischaemic stroke].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2013, Volume: 19, Issue:4

    Topics: Adult; Aged; Anticoagulants; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug The

2013
Switching from aspirin to clopidogrel in patients with aspirin resistance after an ischemic stroke. Is it a good solution?
    European journal of internal medicine, 2014, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Substitution; F

2014
Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:3

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle

2014
Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Substitution; Female; Fibrinolytic Agents

2014
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate

2014
The roles and issues of P2Y12 percent inhibition assessed by VerifyNow assay for patients undergoing Neurointervention: a prospective study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:7

    Topics: Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neur

2014
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.
    Thrombosis research, 2014, Volume: 134, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Ischemia; Cell Adhesion Molecules; China; Clopidog

2014
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    European journal of pharmacology, 2015, Jan-15, Volume: 747

    Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Huma

2015
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:2

    Topics: Aged; Asian People; Brain; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Diffusion Magnetic

2015
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data

2015
Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Flow Cytometry; Human

2015
ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.
    Die Pharmazie, 2015, Volume: 70, Issue:2

    Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Asian People; ATP Binding Cassette Transporter, Subf

2015
Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms.
    Journal of neurointerventional surgery, 2016, Volume: 8, Issue:7

    Topics: Adult; Aged; Brain Ischemia; Clopidogrel; Diffusion Magnetic Resonance Imaging; Embolization, Therap

2016
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:9

    Topics: Aged; Biomarkers, Pharmacological; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Fo

2015
Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate.
    AJNR. American journal of neuroradiology, 2015, Volume: 36, Issue:10

    Topics: Aged; Brain Ischemia; Clopidogrel; Drug Resistance; Embolization, Therapeutic; Female; Humans; Intra

2015
Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy.
    AJNR. American journal of neuroradiology, 2016, Volume: 37, Issue:1

    Topics: Adult; Aged; Alleles; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C

2016
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel;

2015
Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:2

    Topics: Adenosine Diphosphate; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Platele

2016
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
    BMC neurology, 2015, Nov-02, Volume: 15

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies;

2015
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal

2016
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2015, Volume: 32, Issue:6

    Topics: Aged; Alleles; Asian People; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; G

2015
Effect of atorvastatin co-treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:8

    Topics: Aged; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Hydroxymethylglu

2015
Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
    Cerebrovascular diseases (Basel, Switzerland), 2016, Volume: 41, Issue:5-6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Disability E

2016
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
    Journal of the neurological sciences, 2016, Feb-15, Volume: 361

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr

2016
Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention.
    Thrombosis research, 2016, Volume: 138

    Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Diseas

2016
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
    Stroke, 2016, Volume: 47, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Male;

2016
TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke.
    Stroke, 2016, Volume: 47, Issue:5

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; CpG Islands; DNA Methylation; Epigenesis, Gene

2016
Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
    Scientific reports, 2016, 05-03, Volume: 6

    Topics: Aged; Alleles; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male

2016
Extended use of clopidogrel and aspirin after ischemic stroke.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, May-15, Volume: 73, Issue:10

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh

2016
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
    Journal of neurology, 2016, Volume: 263, Issue:8

    Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M

2016
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
    Journal of the American College of Cardiology, 2016, 06-14, Volume: 67, Issue:23

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor

2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Thrombosis research, 2016, Volume: 144

    Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido

2016
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:12

    Topics: Aged; Aged, 80 and over; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-

2016
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Journal of the neurological sciences, 2016, Oct-15, Volume: 369

    Topics: Aged; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hu

2016
Reply to effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with Clopidogrel.
    Journal of the neurological sciences, 2017, Jan-15, Volume: 372

    Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Stro

2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery

2017
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
    Journal of the neurological sciences, 2017, Feb-15, Volume: 373

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2017
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, 02-07, Volume: 12, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther

2017
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
    Postgraduate medical journal, 2017, Volume: 93, Issue:1103

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia

2017
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
    Ideggyogyaszati szemle, 2008, May-30, Volume: 61, Issue:5-6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions;

2008
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest, 2008, Volume: 133, Issue:6 Suppl

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
    European journal of neurology, 2008, Volume: 15, Issue:12

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Dr

2008
Facts and controversies of aspirin and clopidogrel therapy.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos

2009
Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol

2009
Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes.
    Stroke, 2009, Volume: 40, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Cerebral Arteries; Clopidogrel; Fema

2009
Köhlmeier-Degos Disease (malignant atrophic papulosis) and neurologic involvement.
    Arquivos de neuro-psiquiatria, 2009, Volume: 67, Issue:3A

    Topics: Adult; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Malignant Atrophic Papulosis; T

2009
Medical treatment of patients with intracranial atherosclerotic disease.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2009, Volume: 19 Suppl 1

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb

2009
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010, Volume: 30, Issue:2

    Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog

2010
Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".
    American heart journal, 2009, Volume: 158, Issue:6

    Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female

2009
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini

2009
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh

2010
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
    Der Nervenarzt, 2010, Volume: 81, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel;

2010
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
    Current medical research and opinion, 2010, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema

2010
Lateral medullary ischemia presenting with persistent hiccups and vertigo.
    The International journal of neuroscience, 2010, Volume: 120, Issue:3

    Topics: Administration, Oral; Aged; Angiography; Anticoagulants; Brain Ischemia; Clopidogrel; Head Movements

2010
Early stent thrombosis with progressive brainstem infarction in a clopidogrel non-responder.
    Journal of neurology, 2010, Volume: 257, Issue:10

    Topics: Aged; Brain Infarction; Brain Ischemia; Clopidogrel; Disease Progression; Humans; Magnetic Resonance

2010
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
    Stroke, 2010, Volume: 41, Issue:9

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; P

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
An endovascular canine middle cerebral artery occlusion model for the study of leptomeningeal collateral recruitment.
    Investigative radiology, 2011, Volume: 46, Issue:1

    Topics: Angiography; Animals; Anticoagulants; Brain Ischemia; Carotid Arteries; Clopidogrel; Disease Models,

2011
Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
    Atherosclerosis, 2011, Volume: 214, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Down-Reg

2011
Evaluation of clopidogrel resistance in ischemic stroke patients.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:1

    Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female

2011
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
    JPMA. The Journal of the Pakistan Medical Association, 2010, Volume: 60, Issue:10

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B

2010
Fluoxetine and motor recovery after ischaemic stroke.
    The Lancet. Neurology, 2011, Volume: 10, Issue:6

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug

2011
Fluoxetine and motor recovery after ischaemic stroke.
    The Lancet. Neurology, 2011, Volume: 10, Issue:6

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug

2011
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
    Stroke, 2011, Volume: 42, Issue:10

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent;

2011
Acetylsalicylic acid, but not clopidogrel, inhibits therapeutically induced cerebral arteriogenesis in the hypoperfused rat brain.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012, Volume: 32, Issue:1

    Topics: Animals; Aspirin; Brain Ischemia; Cell Line; Cerebral Angiography; Cerebrovascular Circulation; Chem

2012
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response

2012
Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Re

2013
Antiplatelet therapy for transient ischemic attack.
    Journal of clinical hypertension (Greenwich, Conn.), 2012, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders;

2012
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2012, Volume: 83, Issue:6

    Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com

2012
Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
    Stroke, 2012, Volume: 43, Issue:9

    Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Fem

2012
Obesity and intracranial in-stent thrombosis.
    Journal of neurointerventional surgery, 2013, Sep-01, Volume: 5, Issue:5

    Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C

2013
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
    Journal of neurosurgery, 2012, Volume: 117, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina

2012
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br

2013
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012
Ischaemic stroke in young people: a prospective and long-term follow-up study.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 15, Issue:1-2

    Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec

2003
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
    Stroke, 2003, Volume: 34, Issue:12

    Topics: Antigens, CD; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Over Studies;

2003
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Stroke, 2004, Volume: 35, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz

2004
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
    Platelets, 2004, Volume: 15, Issue:1

    Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia;

2004
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
    Deutsche medizinische Wochenschrift (1946), 2004, Mar-19, Volume: 129, Issue:12

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug The

2004
There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Stroke, 2004, Volume: 35, Issue:10

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Pro

2004
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
    The American journal of medicine, 2005, Volume: 118, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular

2005
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex

2005
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
    Neurological research, 2005, Volume: 27, Issue:5

    Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede

2005
[The efficacy of surgical and conservative methods in secondary prevention of carotid ischemic stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2005, Issue:Suppl 13

    Topics: Aged; Brain; Brain Ischemia; Carotid Stenosis; Cerebral Arteries; Clopidogrel; Combined Modality The

2005
[Prophylaxis of stroke].
    Praxis, 2005, Jul-27, Volume: 94, Issue:30-31

    Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi

2005
Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress.
    Pathophysiology of haemostasis and thrombosis, 2005, Volume: 34, Issue:1

    Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Age Factors; Aged; Aspirin; Blood Platelets; Brain Ischemia;

2005
The risks and safety of clopidogrel in pediatric arterial ischemic stroke.
    Stroke, 2006, Volume: 37, Issue:4

    Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Clopidogrel; Cohort Studies; Drug Ther

2006
High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
    Pharmacotherapy, 2006, Volume: 26, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Hospitaliz

2006
Enhanced platelet activation by prolactin in patients with ischemic stroke.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran

2006
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
    Clinical hemorheology and microcirculation, 2006, Volume: 35, Issue:1-2

    Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl

2006
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:7

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St

2006
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose-

2006
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
    Current neurovascular research, 2007, Volume: 4, Issue:1

    Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem

2007
Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients.
    Drugs & aging, 2007, Volume: 24, Issue:4

    Topics: Adult; Aged; Alleles; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Age

2007
Rate, degree, and predictors of recovery from disability following ischemic stroke.
    Neurology, 2007, May-08, Volume: 68, Issue:19

    Topics: Aged; Brain Ischemia; Causality; Clopidogrel; Cohort Studies; Diabetes Complications; Disability Eva

2007
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
    Ugeskrift for laeger, 2007, Oct-01, Volume: 169, Issue:40

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents;

2007
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru

2008
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;

2008
[Antithrombotic therapy in operations on extracranial arteries].
    Vestnik khirurgii imeni I. I. Grekova, 2008, Volume: 167, Issue:1

    Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Endarterectomy, Carotid; Female; Fibri

2008
[Ticlopidine in the prevention of recurrent cerebral ischemic accidents].
    Medicina clinica, 1984, Oct-20, Volume: 83, Issue:12

    Topics: Anticoagulants; Brain Ischemia; Humans; Recurrence; Thiophenes; Ticlopidine

1984
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
    Medicina clinica, 1984, Jan-21, Volume: 82, Issue:2

    Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Re

1984
Essential thrombocytemia and ischemic stroke: report of six cases.
    Italian journal of neurological sciences, 1994, Volume: 15, Issue:7

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Magnetic Resonance Imaging

1994
Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease.
    Stroke, 1995, Volume: 26, Issue:1

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Cerebral Angiography; Cerebrovascu

1995
Ischemic stroke, Part 2: Optimal treatment and prevention.
    Geriatrics, 1993, Volume: 48, Issue:3

    Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F

1993
[Stroke in young people].
    Revista de neurologia, 1996, Volume: 24, Issue:126

    Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Child; Dipyridamole; Female; Humans; Male; Middle Aged;

1996
[Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin].
    Revista de neurologia, 1996, Volume: 24, Issue:126

    Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Female; Humans; Male; Platelet Aggregation Inhibito

1996
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Costs; Humans; Platelet Aggregation Inhibitors; Randomize

1997
[Bilateral hypoacusia and basilar dolichoectasia].
    Revista de neurologia, 1996, Volume: 24, Issue:136

    Topics: Audiometry, Pure-Tone; Basilar Artery; Brain Ischemia; Cerebral Angiography; Hearing Loss, Sensorine

1996
[Acetylsalicylic acid in ischemic insult].
    Deutsche medizinische Wochenschrift (1946), 1998, Feb-27, Volume: 123, Issue:9

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P

1998
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
    Clinical therapeutics, 1998, Volume: 20 Suppl B

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa

1998
[Prevention of thrombosis after ischemic cerebrovascular attack--new possibilities].
    Ugeskrift for laeger, 1998, Jul-20, Volume: 160, Issue:30

    Topics: Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Intracranial Embolism

1998
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
    The American journal of medicine, 1999, Volume: 107, Issue:6

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C

1999
[Ticlopidine-associated thrombotic thrombocytopenic purpura (Morbus Moschcowitz)].
    Medizinische Klinik (Munich, Germany : 1983), 2000, Jan-15, Volume: 95, Issue:1

    Topics: Aged; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Fatal Outcome; Female; Humans; P

2000
Cerebrovascular disease associated with marijuana abuse: a case report.
    Cerebrovascular diseases (Basel, Switzerland), 2001, Volume: 11, Issue:3

    Topics: Adult; Brain; Brain Ischemia; Cerebral Infarction; Fibrinolytic Agents; Humans; Magnetic Resonance I

2001
CURE--clopidogrel's major advance.
    International journal of clinical practice, 2001, Volume: 55, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate

2001
Protective effects of benidipine on arachidonic acid-induced acute cerebral ischemia in rats.
    Japanese journal of pharmacology, 1992, Volume: 59, Issue:1

    Topics: Animals; Arachidonic Acid; Benzoquinones; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Calcium

1992
[Drug treatment of ischemic disturbances of circulation in the brain].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:20

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Ticlopidine

1990
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
    Stroke, 1989, Volume: 20, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P

1989
[Antiplatelet effects of combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia].
    Rinsho shinkeigaku = Clinical neurology, 1989, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans;

1989
Validation of cognitive and functional assessment instruments in vascular dementia.
    International journal of psychiatry in medicine, 1987, Volume: 17, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Dementia; Double-Blind Method; Female; Humans; Mal

1987